Media coverage about Adamas Pharmaceuticals (NASDAQ:ADMS) has been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamas Pharmaceuticals earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 45.6777305895053 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Adamas Pharmaceuticals Inc (ADMS) Analyst Explains Why Osmotica’s FDA Approved Drug Isn’t a Viable Threat (smarteranalyst.com)
- 3 Biotech Stocks To Avoid (finance.yahoo.com)
- Why Adamas Pharmaceuticals Fell Today (finance.yahoo.com)
- Intentions Seeker Stock: Adamas Pharma Cmn (ADMS) – Emn News (emnnews.com)
- Adamas Pharma (ADMS) Presents At Leerink Partners 7th Annual Global Healthcare Conference – Slideshow (seekingalpha.com)
Adamas Pharmaceuticals (NASDAQ:ADMS) opened at $26.39 on Wednesday. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41. The firm has a market cap of $883.64, a PE ratio of -7.83 and a beta of 1.17. Adamas Pharmaceuticals has a 1 year low of $13.50 and a 1 year high of $44.00.
ADMS has been the topic of several recent research reports. Evercore ISI initiated coverage on shares of Adamas Pharmaceuticals in a research note on Monday, October 30th. They set an “outperform” rating on the stock. Noble Financial lifted their target price on shares of Adamas Pharmaceuticals from $33.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Northland Securities initiated coverage on shares of Adamas Pharmaceuticals in a research note on Wednesday, November 29th. They set an “outperform” rating on the stock. Cowen set a $55.00 target price on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, December 13th. Finally, BidaskClub cut shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 14th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $44.86.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.